170 related articles for article (PubMed ID: 19204870)
41. Minimal influence of metallothionein over-expression on nickel carcinogenesis in mice.
Waalkes MP; Liu J; Kasprzak KS; Diwan BA
Toxicol Lett; 2004 Nov; 153(3):357-64. PubMed ID: 15454311
[TBL] [Abstract][Full Text] [Related]
42. Renoprotection From Diabetic Complications in OVE Transgenic Mice by Endothelial Cell Specific Overexpression of Metallothionein: A TEM Stereological Analysis.
Carlson EC; Chhoun JM; Grove BD; Laturnus DI; Zheng S; Epstein PN; Tan Y
Anat Rec (Hoboken); 2017 Mar; 300(3):560-576. PubMed ID: 27813325
[TBL] [Abstract][Full Text] [Related]
43. Resolvin D1 protects podocytes in adriamycin-induced nephropathy through modulation of 14-3-3β acetylation.
Zhang X; Qu X; Sun YB; Caruana G; Bertram JF; Nikolic-Paterson DJ; Li J
PLoS One; 2013; 8(6):e67471. PubMed ID: 23840712
[TBL] [Abstract][Full Text] [Related]
44. Osteocrin ameliorates adriamycin nephropathy via p38 mitogen-activated protein kinase inhibition.
Handa T; Mori KP; Ishii A; Ohno S; Kanai Y; Watanabe-Takano H; Yasoda A; Kuwabara T; Takahashi N; Mochizuki N; Mukoyama M; Yanagita M; Yokoi H
Sci Rep; 2021 Nov; 11(1):21835. PubMed ID: 34750411
[TBL] [Abstract][Full Text] [Related]
45. Re-expression of Sall1 in podocytes protects against adriamycin-induced nephrosis.
Hosoe-Nagai Y; Hidaka T; Sonoda A; Sasaki Y; Yamamoto-Nonaka K; Seki T; Asao R; Tanaka E; Trejo JAO; Kodama F; Takagi M; Tada N; Ueno T; Nishinakamura R; Tomino Y; Asanuma K
Lab Invest; 2017 Nov; 97(11):1306-1320. PubMed ID: 28759006
[TBL] [Abstract][Full Text] [Related]
46. Podocyte foot process effacement in very early phase of passive Heymann nephritis is not a prerequisite for proteinuria.
Nosaka H; Tamura Y; Kojima K; Uchida S; Nagase M
J Nephrol; 2009; 22(4):484-90. PubMed ID: 19662603
[TBL] [Abstract][Full Text] [Related]
47. Thrombospondin 1 Deficiency Ameliorates the Development of Adriamycin-Induced Proteinuric Kidney Disease.
Maimaitiyiming H; Zhou Q; Wang S
PLoS One; 2016; 11(5):e0156144. PubMed ID: 27196103
[TBL] [Abstract][Full Text] [Related]
48. Ameliorating Effect of Gemigliptin on Renal Injury in Murine Adriamycin-Induced Nephropathy.
Kim DR; Lee SY; Kim JS; Kim YG; Moon JY; Lee SH; Lee TW; Ihm CG; Jeong KH
Biomed Res Int; 2017; 2017():7275109. PubMed ID: 28326327
[No Abstract] [Full Text] [Related]
49. Metallothionein-I-transgenic mice are not protected from acute cadmium-metallothionein-induced nephrotoxicity.
Liu YP; Liu J; Palmiter RD; Klaassen CD
Toxicol Appl Pharmacol; 1996 Apr; 137(2):307-15. PubMed ID: 8661357
[TBL] [Abstract][Full Text] [Related]
50. SIRPα signaling regulates podocyte structure and function.
Takahashi S; Tomioka M; Hiromura K; Sakairi T; Hamatani H; Watanabe M; Ikeuchi H; Kaneko Y; Maeshima A; Aoki T; Ohnishi H; Matozaki T; Nojima Y
Am J Physiol Renal Physiol; 2013 Sep; 305(6):F861-70. PubMed ID: 23842779
[TBL] [Abstract][Full Text] [Related]
51. Nitro-oleic acid protects against adriamycin-induced nephropathy in mice.
Liu S; Jia Z; Zhou L; Liu Y; Ling H; Zhou SF; Zhang A; Du Y; Guan G; Yang T
Am J Physiol Renal Physiol; 2013 Dec; 305(11):F1533-41. PubMed ID: 23486011
[TBL] [Abstract][Full Text] [Related]
52. Interleukin-7 stimulation inhibits nephrin activation and induces podocyte injury.
Zhai S; Zhao L; Zhang Y; Ma Q
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):100-105. PubMed ID: 30454893
[TBL] [Abstract][Full Text] [Related]
53. The podocyte in health and disease: insights from the mouse.
Michaud JL; Kennedy CR
Clin Sci (Lond); 2007 Jun; 112(6):325-35. PubMed ID: 17291194
[TBL] [Abstract][Full Text] [Related]
54. Distinct roles for basal and induced COX-2 in podocyte injury.
Cheng H; Fan X; Guan Y; Moeckel GW; Zent R; Harris RC
J Am Soc Nephrol; 2009 Sep; 20(9):1953-62. PubMed ID: 19643929
[TBL] [Abstract][Full Text] [Related]
55. Adriamycin and adriamycin-DNA nephrotoxicity in rats.
Giroux L; Smeesters C; Boury F; Faure MP; Jean G
Lab Invest; 1984 Feb; 50(2):190-6. PubMed ID: 6607380
[TBL] [Abstract][Full Text] [Related]
56. (Pro)renin receptor decoy peptide PRO20 protects against adriamycin-induced nephropathy by targeting the intrarenal renin-angiotensin system.
Luo R; Yang K; Wang F; Xu C; Yang T
Am J Physiol Renal Physiol; 2020 Nov; 319(5):F930-F940. PubMed ID: 32865014
[TBL] [Abstract][Full Text] [Related]
57. Mesenchymal stem cells protective effect in adriamycin model of nephropathy.
Magnasco A; Corselli M; Bertelli R; Ibatici A; Peresi M; Gaggero G; Cappiello V; Chiavarina B; Mattioli G; Gusmano R; Ravetti JL; Frassoni F; Ghiggeri GM
Cell Transplant; 2008; 17(10-11):1157-67. PubMed ID: 19181210
[TBL] [Abstract][Full Text] [Related]
58. Evaluation of adriamycin nephropathy by an in vivo electron paramagnetic resonance.
Oteki T; Nagase S; Yokoyama H; Ohya H; Akatsuka T; Tada M; Ueda A; Hirayama A; Koyama A
Biochem Biophys Res Commun; 2005 Jul; 332(2):326-31. PubMed ID: 15910741
[TBL] [Abstract][Full Text] [Related]
59. [Protective effects of Shenkangwan against podocyte injury in rats with early diabetic nephropathy].
Long HB; Zhang H; Zhong J; Zhu Y; He JH; Wei LB
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Jul; 28(7):1268-72. PubMed ID: 18676280
[TBL] [Abstract][Full Text] [Related]
60. Zinc prevents indomethacin-induced renal damage in rats by ameliorating oxidative stress and mitochondrial dysfunction.
Varghese J; Faith M; Jacob M
Eur J Pharmacol; 2009 Jul; 614(1-3):114-21. PubMed ID: 19445918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
